BMS-754807

Catalog No.S1124

Molecular Weight(MW): 461.49

BMS-754807 is a potent and reversible inhibitor of IGF-1R/InsR with IC50 of 1.8 nM/1.7 nM in cell-free assays, less potent to Met, Aurora A/B, TrkA/B and Ron, and shows little activity to Flt3, Lck, MK2, PKA, PKC etc. Phase 2.

Cited by 6 Publications

Clin Cancer Res, 2013, 19(11):2984-94

PubMed: 23549869 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5866-77

PubMed: 25168481 ( click the link to review the publication )

Mol Cell Biol, 2015, 35(7):1182-96

PubMed: ( click the link to review the publication )

Cellular Signalling, 2016, 19;28(6):652-662

PubMed: 27006333 ( click the link to review the publication )

Brain Res, 2018, 1678:407-418

PubMed: 29137974 ( click the link to review the publication )

PLoS One, 2015, 10(5):e0126867

PubMed: 25962155 ( click the link to review the publication )

1 Customer Review

Clin Cancer Res 2013 19(11), 2984-94. BMS-754807 purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description

Features

Muti-inhibitor of the IGR-1R/IR family.

Targets

Insulin Receptor ^[1] (Cell-free assay)	IGF-1R ^[1] (Cell-free assay)	TrkB ^[1] (Cell-free assay)	Met ^[1] (Cell-free assay)	TrkA ^[1] (Cell-free assay)	View More
1.7 nM	1.8 nM	4.1 nM	5.6 nM	7.4 nM	View More

In vitro

BMS-754807 effectively inhibits the growth of a broad range of human tumor cell lines of different histologic origins including mesenchymal (Ewing's, rhabdomyosarcoma, neuroblastoma, and liposarcoma), epithelial (breast, lung, pancreatic, colon, and gastric), and hematopoietic (multiple myeloma and leukemia), the IC50 values range from 5 nM to 365 nM for the most sensitive cell lines. BMS-754807 inhibits proliferation of IGF-1R-Sal cells and RH41 cells with IC50 of 7 nM and 5 nM. BMS-754807 inhibits phosphorylation of IGF-1R in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 13 nM, 6 nM and 21 nM. BMS-754807 inhibits phosphorylation of Akt in IGF-1R-Sal cells, Rh41 and Geo with IC50 of 22 nM, 13 nM and 16 nM. BMS-754807 induces greater apoptosis in Rh41 cells by 24 hours as indicated by an increased sub-G1 peak (23.1%), compared with control (2.4%). ^[1] BMS-754807 inhibits the phosphorylation of IGF-1R (IC50 = 13nM) and the downstream targets Akt (IC50 = 22nM) and MAPK (IC50 = 13nM) in the IGF-Sal cell line with IC50 consistent with the antiproliferative IC50 (7 nM) in this cell line. The crystal structure of BMS-754807 cocrystallized with the kinase domain of IGF-1R shows that the donor/acceptor/donor hydrogen bond triad with Met1052 and Glu1050 within the hinge region of the kinase. ^[2] BMS-754807 shows a median EC50 value of 0.62 μM against 23 cell lines in the pediatric preclinical testing program (PPTP). ^[3]

Cell Data

Cell Lines	Assay Type	Concentration	Formulation	Activity Description	PMID
IGF-Sal	MV;LbY5ie2ViYYPzZZk>			M3S0ZYlvcGmkaYTzJJRp\SCyaH;zdIhwenmuYYTpc44hd2ZiSVfGMVFTKCiLQ{WwJF0hOTOwTTmgZY5lKHSqZTDkc5dve3S{ZXHtJJRiemendIOgRYt1KCiLQ{WwJF0hOjKwTTmgZY5lKE2DUFugLGlEPTBiPTCxN45OMQ>?	MoX1NVk4PzhyMkS=
IGF-Sal	MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?			NW\qeIRVUUN3ME23JI5O	M2[yblE6Pzd6MEK0
CCRF-CEM (ALL)	MlHoS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYH+OUDPxE1?	MkWwSG1UVw>?	M3S2eWlEPTB;MT6yN\|kh\|ryP	Mmi0NVk6QTZ{N{K=
PC3	NULXblRrT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIW4[5Z,PSEQvF2=	NX[zelVZTE2VTx?=	NHG2VoNKSzVyPUCuPVY2KM7:TR?=	NGj0NG0yQTl7NkK3Ni=>
JD	NX31Z4puT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4mwPZ42KM7:TR?=	MVrEUXNQ	NH34RnNKSzVyPUCuN\|kyKM7:TR?=	M3G1TlE6QTl4Mkey
DU145	NF3oNnVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NYDiPJVqhjVizszN	MVLEUXNQ	Ml[xTWM2OD1zLkS2OUDPxE1?	NVv6UodJOTl7OU[yO\|I>
KAG	NUPXUoFmT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MWH+OUDPxE1?	Mm\USG1UVw>?	M1fuXmlEPTB;MT62OlUh\|ryP	NH;PVWYyQTl7NkK3Ni=>
K-562 (CML)	NU\EemFWT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmnNglUh\|ryP	NYfFdXlLTE2VTx?=	MlzMTWM2OD1{LkOwNkDPxE1?	MUOxPVk6PjJ5Mh?=
B6-P210 (Murine ALL)	NXPTe\|lYT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mnz2glUh\|ryP	NGjmdW1FVVOR	Mlj3TWM2OD1zLkK5N{DPxE1?	NV;qR\|RUOTl7OU[yO\|I>
LN CAP-FGC	NYrt[XdsT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYPiUJdjhjVizszN	Mn7GSG1UVw>?	NHnCfHdKSzVyPUGuOFM1KM7:TR?=	MVqxPVk6PjJ5Mh?=
VW	M1jneGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NX7RPY97hjVizszN	M1XmcGROW09?	MVPJR\|UxRTBwMEG5JO69VQ>?	MmP4NVk6QTZ{N{K=
MV411 (B Myelomonocytic)	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1PZZZ42KM7:TR?=	NFvCbpdFVVOR	Mk\jTWM2OD1yLkOzJO69VQ>?	NWToWVU3OTl7OU[yO\|I>
MDA-PCa-2b	MlG1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4\E[p42KM7:TR?=	NX\TTY5iTE2VTx?=	NY\aRnFmUUN3ME2wMlA6QCEQvF2=	M1fzN\|E6QTl4Mkey
LG	M371Wmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1K0VJ42KM7:TR?=	Ml7USG1UVw>?	MnfUTWM2OD1yLkCzPEDPxE1?	NVXDW5d7OTl7OU[yO\|I>
RS411 (B cell precursor-ALL)	M2TxdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NY\oVZdrhjVizszN	MlzLSG1UVw>?	Mlz4TWM2OD1yLkGwNkDPxE1?	M3nzT\|E6QTl4Mkey
22-r-1	NFm3XlVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MUP+OUDPxE1?	MnPNSG1UVw>?	NIjlb5lKSzVyPUCuNVc2KM7:TR?=	M1TLSVE6QTl4Mkey
5838	MorBS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoDrglUh\|ryP	NWTINmVTTE2VTx?=	M2\ISGlEPTB;MD6wN\|Qh\|ryP	Mnm5NVk6QTZ{N{K=
P388 (Murine)	MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3zTSZ42KM7:TR?=	Mle0SG1UVw>?	MWHJR\|UxRTRwMkeg{txO	MXWxPVk6PjJ5Mh?=
A2780/S	NXTyeoQ3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mn\SglUh\|ryP	NHzJd25FVVOR	MVfJR\|UxRTBwMUKyJO69VQ>?	MUWxPVk6PjJ5Mh?=
RDES	M{jrfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NGWzXnN,PSEQvF2=	NFfmNHBFVVOR	M4rrcWlEPTB;MD6wNVIh\|ryP	M2HRPVE6QTl4Mkey
B6-T315I (Murine B-ALL)	MmK3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M4jNdJ42KM7:TR?=	M{fxT2ROW09?	M{TK[GlEPTB;Mj64N{DPxE1?	MWexPVk6PjJ5Mh?=
TOV 112D	Mo\MS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3LzXJ42KM7:TR?=	MW\EUXNQ	NYXGbWpXUUN3ME2yMlE1PiEQvF2=	NITBeIYyQTl7NkK3Ni=>
TC32	NYjaRXRmT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NH3KOld,PSEQvF2=	NUDZWJlpTE2VTx?=	NIXYSJNKSzVyPUCuNFA5KM7:TR?=	M4PFc\|E6QTl4Mkey
HL60 (acute myelocytic)	NH3oTVRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2rVep42KM7:TR?=	M4\mNWROW09?	NIPLVG1KSzVyPUCuNVIh\|ryP	MmjDNVk6QTZ{N{K=
TOV 21G	NH3jSGpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1;odZ42KM7:TR?=	NFH5fYFFVVOR	NW\Tb5B7UUN3ME20MlI4QSEQvF2=	M1vKXlE6QTl4Mkey
TC71	M1Hxcmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUDNR4lihjVizszN	NHToZ3dFVVOR	MofrTWM2OD1yLkCxOEDPxE1?	NWHmTm1{OTl7OU[yO\|I>
HPN-ALL (T-cell)	NX35bXV5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnPiglUh\|ryP	MmnBSG1UVw>?	NIjQblJKSzVyPUCuOVIh\|ryP	NHzIfFcyQTl7NkK3Ni=>
A2780R	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	Mnq1glUh\|ryP	M4HmcWROW09?	NHG5XWZKSzVyPUGuOVY1KM7:TR?=	MXuxPVk6PjJ5Mh?=
Rh1	MmWzS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHHWeFN,PSEQvF2=	NVL0S\|hrTE2VTx?=	NF[yVmhKSzVyPUCuNFI4KM7:TR?=	MYOxPVk6PjJ5Mh?=
Kasumi-1 (acute myeloid)	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3[wV542KM7:TR?=	MWXEUXNQ	MXPJR\|UxRTBwMU[g{txO	NVfD[mExOTl7OU[yO\|I>
sk-ov-3	NF:5NlZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUjLXFU4hjVizszN	MmPNSG1UVw>?	NV[3N4VtUUN3ME21MlEh\|ryP	MkX6NVk6QTZ{N{K=
ME	M1nrS2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFTHU2Z,PSEQvF2=	NHrFUWVFVVOR	M3\VVmlEPTB;MD6wNVUh\|ryP	MYmxPVk6PjJ5Mh?=
L1210 (Murine lymphocytic)	M1HIO2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MkSxglUh\|ryP	M2TPVmROW09?	MmXQTWM2OD1{LkO5JO69VQ>?	NFT0fVEyQTl7NkK3Ni=>
sw-626	NIDEU2tIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M1POdZ42KM7:TR?=	Mkf3SG1UVw>?	Mlu2TWM2OD1{LkOwOkDPxE1?	M1jnWlE6QTl4Mkey
CTR	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MmHFglUh\|ryP	MnLVSG1UVw>?	Mn;pTWM2OD1yLkK1N{DPxE1?	MWmxPVk6PjJ5Mh?=
ML2 (Myelomonocytic)	NYLxWHl3T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	Mkf6glUh\|ryP	MXjEUXNQ	MkD0TWM2OD1yLkC5JO69VQ>?	MmL1NVk6QTZ{N{K=
ovcar-3	M1LNcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NFLUfoN,PSEQvF2=	NHrtdFZFVVOR	MkLFTWM2OD13IN88US=>	MW[xPVk6PjJ5Mh?=
Rh36	NEPpXopIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M173Np42KM7:TR?=	Moi5SG1UVw>?	MmjTTWM2OD1zLkSzNkDPxE1?	M3ewbVE6QTl4Mkey
MOLM-13 (acute myeloid)	M3jhbGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NES0Rox,PSEQvF2=	NYHpXIVuTE2VTx?=	NIqyelRKSzVyPUCuOFIh\|ryP	M3v6PVE6QTl4Mkey
ovcar-4	NEiyNGRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MknHglUh\|ryP	NI\lVJpFVVOR	MYjJR\|UxRTFizszN	NHLhWGIyQTl7NkK3Ni=>
Rh41	NYP4[mJmT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYD+OUDPxE1?	MmixSG1UVw>?	MnX6TWM2OD1yLkCwOUDPxE1?	M{fRNVE6QTl4Mkey
Mutz 2 (acute myeloid)	Mn\SS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M{[3TZ42KM7:TR?=	MYfEUXNQ	MXTJR\|UxRTFwMUWg{txO	NFW5NVIyQTl7NkK3Ni=>
ovcar-5	NH3aUodIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVHkbFByhjVizszN	MnTvSG1UVw>?	NETuU49KSzVyPUCuNFUh\|ryP	MUKxPVk6PjJ5Mh?=
RD1	MlH0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2rs[Z42KM7:TR?=	MVTEUXNQ	MUPJR\|UxRTBwME[4JO69VQ>?	MYSxPVk6PjJ5Mh?=
OCI-AML 2 (acute myeloid)	NFrINJZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MV;+OUDPxE1?	NFvCfY1FVVOR	NYm1bGk1UUN3ME2zMlM{KM7:TR?=	M4\ZTVE6QTl4Mkey
786-O	NF;hRmJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHXkW3F,PSEQvF2=	NY\kSYpTTE2VTx?=	M3r4d2lEPTB;MT62OFch\|ryP	NF\TPZoyQTl7NkK3Ni=>
A673	M1;lNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXyy[lNnhjVizszN	NG[0cY5FVVOR	M13tUGlEPTB;MD60NFgh\|ryP	MVixPVk6PjJ5Mh?=
TALL-1 (T-cell)	M4Huemdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmjFglUh\|ryP	NEX2fm1FVVOR	NGjENoRKSzVyPUGuNlgh\|ryP	Mm\GNVk6QTZ{N{K=
151-B	M1Xlfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4LEW542KM7:TR?=	MXPEUXNQ	MXXJR\|UxRTJwNkeg{txO	M1TtXlE6QTl4Mkey
PFSK-1	NVjldFFVT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MmD4glUh\|ryP	NUH6dXo5TE2VTx?=	NYXDOGpVUUN3ME2wMlE{OiEQvF2=	M{LGV\|E6QTl4Mkey
THP-1	MoOxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWX1eGpDhjVizszN	MorPSG1UVw>?	MWDJR\|UxRTZwNUig{txO	Mo\rNVk6QTZ{N{K=
HEK293	MoLNS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M1G4TZ42KM7:TR?=	NVLvc4tCTE2VTx?=	NXznR3dFUUN3ME2wMlkyPSEQvF2=	MWqxPVk6PjJ5Mh?=
DAOY	M2XEbWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M4XFV542KM7:TR?=	NITQUGVFVVOR	M2LBdmlEPTB;MT65O\|kh\|ryP	Mlj5NVk6QTZ{N{K=
SET2	NYTtWWt6T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M13FN542KM7:TR?=	NVX2bGJRTE2VTx?=	NETvd3VKSzVyPUCuNlk5KM7:TR?=	Mlu1NVk6QTZ{N{K=
HTB-46	NYPaUmNmT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1qyXZ42KM7:TR?=	M4LLXmROW09?	MUTJR\|UxRTVwMkWg{txO	NVG0ZZpKOTl7OU[yO\|I>
SK-NAS	NX7E[3VYT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M4Pl[J42KM7:TR?=	MWDEUXNQ	MX7JR\|UxRTBwNEm3JO69VQ>?	NEXOXm8yQTl7NkK3Ni=>
CTLL2	MkHCS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NWLVbYt2hjVizszN	NUjWU3YzTE2VTx?=	NET0PHNKSzVyPkGuNFAh\|ryP	M{\ldlE6QTl4Mkey
HTB-47	NIPxT2ZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2G0Rp42KM7:TR?=	NEXXdlFFVVOR	MnnyTWM2OD1{LkC1OkDPxE1?	NFfz[ogyQTl7NkK3Ni=>
LAN-1	MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MnzvglUh\|ryP	NXzQeo01TE2VTx?=	M{nld2lEPTB;MD6wOEDPxE1?	NX3kOYpZOTl7OU[yO\|I>
ST486	NIPWeGVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmDlglUh\|ryP	NILEd\|RFVVOR	M1TofmlEPTB;MT6xPUDPxE1?	M1rsN\|E6QTl4Mkey
HS766T	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWL+OUDPxE1?	M4\hWmROW09?	NHm0Oo5KSzVyPUKuNFAyKM7:TR?=	Mnq3NVk6QTZ{N{K=
IMR-32	MmO1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MXX+OUDPxE1?	Mmm1SG1UVw>?	Mk\rTWM2OD1yLkK2NUDPxE1?	NXjhT2M{OTl7OU[yO\|I>
Daudi (Burkitt's)	NYrjcoc1T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M{m4cZ42KM7:TR?=	M1qwSWROW09?	MmDzTWM2OD1{Lk[zO{DPxE1?	M3uxUlE6QTl4Mkey
Aspc-1	M3P2TGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M33wV542KM7:TR?=	NXK2Ro96TE2VTx?=	NET2fIlKSzVyPUCuN\|c6KM7:TR?=	NV;hXXBmOTl7OU[yO\|I>
SK-NSH	M4HmN2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYrmUZE5hjVizszN	M1rO[mROW09?	MVPJR\|UxRTBwMUO5JO69VQ>?	MnHINVk6QTZ{N{K=
MEC-1 (Chronic B cell)	NEPUemtIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVn+OUDPxE1?	MoTJSG1UVw>?	MoP5TWM2OD1{Lk[zO{DPxE1?	M3XsdFE6QTl4Mkey
Capan-2	M1rZcGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUjlTYJ7hjVizszN	MUXEUXNQ	NF\Z[VhKSzVyPUGuO\|c1KM7:TR?=	MnLLNVk6QTZ{N{K=
SHSY5Y	NIfzSZpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MV7+OUDPxE1?	Ml\PSG1UVw>?	NW\SUmVRUUN3ME2wMlExPiEQvF2=	M1vvTVE6QTl4Mkey
U937 (Histioocytic)	MoHLS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWH+OUDPxE1?	MlfrSG1UVw>?	NIjRXY5KSzVyPkWuNFAh\|ryP	MoT5NVk6QTZ{N{K=
Bxpc-1	MVrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4PYV542KM7:TR?=	NIHIU3ZFVVOR	MUXJR\|UxRTFwOUK0JO69VQ>?	MVmxPVk6PjJ5Mh?=
Bxpc-3	NHjmPIpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NF31V2d,PSEQvF2=	M134PGROW09?	MXzJR\|UxRjVwMECg{txO	MX6xPVk6PjJ5Mh?=
HTB-92	M3\lVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYTzbXpEhjVizszN	NYrzNGtNTE2VTx?=	NEG3Z\|NKSzVyPUGuNFIh\|ryP	NXu2R5JEOTl7OU[yO\|I>
OCI-LY10 (B-cell)	MYrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NGTze\|B,PSEQvF2=	MoHiSG1UVw>?	MnPyTWM2OD1yLkS1JO69VQ>?	NHnJXWwyQTl7NkK3Ni=>
PANC-1	NVHDTWI{T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MYr+OUDPxE1?	NWLje2kzTE2VTx?=	M{\DdWlEPTB-NT6wNEDPxE1?	NI\rNVMyQTl7NkK3Ni=>
To184.T	NIDnfnRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NVf4bmFUhjVizszN	NVjodItwTE2VTx?=	M3zOOmlEPTB;MD60Olkh\|ryP	NFHWPJUyQTl7NkK3Ni=>
OCI-LY19 (B-cell)	MU\Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWT+OUDPxE1?	NEDLdm5FVVOR	Mmj1TWM2OD1yLkSg{txO	NIPCS\|gyQTl7NkK3Ni=>
PANC-1 BM	Ml61S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWP+OUDPxE1?	MmTPSG1UVw>?	NVjteZpHUUN3ME61MlAxKM7:TR?=	MkDGNVk6QTZ{N{K=
SA-4	NETBOI5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2OyfJ42KM7:TR?=	MYDEUXNQ	NYLMeJBJUUN3ME2xMlMxOSEQvF2=	M1\mUVE6QTl4Mkey
RPMI 8226	NFHoeHNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MnH0glUh\|ryP	MYjEUXNQ	M2TRfWlEPTB;MT6yPVMh\|ryP	MVKxPVk6PjJ5Mh?=
HPAF-II	NGXYWlVIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NEfRelF,PSEQvF2=	NGi4U4tFVVOR	MWTJR\|UxRTBwNkS0JO69VQ>?	NFKwdHcyQTl7NkK3Ni=>
SHP-77	MVjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MX3+OUDPxE1?	NVqzZ2tVTE2VTx?=	M1zYVmlEPTB;MT64PFgh\|ryP	M3PjR\|E6QTl4Mkey
U266 B1	M4O4fGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2DhOZ42KM7:TR?=	MUHEUXNQ	MWPJR\|UxRTFwNk[5JO69VQ>?	M{f3bVE6QTl4Mkey
Hs700t	MYjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVz+OUDPxE1?	NEXWNo5FVVOR	NVPENpJIUUN3ME2wMlI{OSEQvF2=	M3TWOFE6QTl4Mkey
NCI-446	NH[2RpBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHrKfmt,PSEQvF2=	MkHzSG1UVw>?	MkjETWM2OD1zLkG1OEDPxE1?	NXHhTJhoOTl7OU[yO\|I>
H929	MoP1S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnTEglUh\|ryP	M2T5ZmROW09?	NVe4emxlUUN3ME2wMlAyPCEQvF2=	M2fieFE6QTl4Mkey
PL45	MnO0S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MojZglUh\|ryP	NWLTcW1vTE2VTx?=	M1HJc2lEPTB;Mj6yOVUh\|ryP	MYqxPVk6PjJ5Mh?=
NCI-H383	MoLSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MWX+OUDPxE1?	M{jCWGROW09?	NGPndIJKSzVyPkWuNFAh\|ryP	MX[xPVk6PjJ5Mh?=
JJN3	NGXUendIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHnpNoR,PSEQvF2=	NWW3S\|RlTE2VTx?=	NXzoZWJiUUN3ME2yMlQ{OyEQvF2=	NFXVfpMyQTl7NkK3Ni=>
SU.86.86	Mn;iS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NEiyV5h,PSEQvF2=	M4Txd2ROW09?	M{X3TWlEPTB;Mj62O\|Ih\|ryP	MVKxPVk6PjJ5Mh?=
H1299	NX3z[GU4T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NYDUTWxZhjVizszN	MlP0SG1UVw>?	MXjJR\|UxRjVwMECg{txO	MoTGNVk6QTZ{N{K=
MDA-MB-468	MmfkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NGfrcYt,PSEQvF2=	NGLKOlVFVVOR	MVTJR\|UxRTBwNUC0JO69VQ>?	NVjKRmxSOTl7OU[yO\|I>
SW1990	M3r0Omdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NUP0RXFPhjVizszN	MYTEUXNQ	M3LxU2lEPTB;MD64NlYh\|ryP	M3\obFE6QTl4Mkey
Calu-6	MlrFS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	Mne0glUh\|ryP	MlX6SG1UVw>?	MX7JR\|UxRjVwMECg{txO	NH7nOlAyQTl7NkK3Ni=>
MDA-MB-231	NWnwNotGT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M3rLN542KM7:TR?=	MkHmSG1UVw>?	MXjJR\|UxRTFwNkS4JO69VQ>?	NXrYcpdFOTl7OU[yO\|I>
SW-684	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1HsV542KM7:TR?=	MVHEUXNQ	M3HEZWlEPTB-NT6wNEDPxE1?	Mn;KNVk6QTZ{N{K=
H209	Ml7wS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NIHrO4Z,PSEQvF2=	NInqcVlFVVOR	M1nsc2lEPTB;MT6xPVMh\|ryP	MkLNNVk6QTZ{N{K=
MDA-MB-231T	M2LtTmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NXPYeJlyhjVizszN	MV3EUXNQ	M4LhfmlEPTB-NT6wNEDPxE1?	NUjBUmlbOTl7OU[yO\|I>
HT1080/S	NYLDN2hpT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NID0NVR,PSEQvF2=	Mn;JSG1UVw>?	M{PDZmlEPTB;MD61N\|Eh\|ryP	MV2xPVk6PjJ5Mh?=
H526 0.044	MlfxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MX\+OUDPxE1?	MmThSG1UVw>?	NFG1dFVKSzVyPUCuNFQ1KM7:TR?=	NFLRSlkyQTl7NkK3Ni=>
DU4475 2.431	MVnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1;4dp42KM7:TR?=	NFm0OppFVVOR	NYT0bWxzUUN3ME2yMlQ{OSEQvF2=	Mn:wNVk6QTZ{N{K=
HCT116	NIfHN\|BIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NE\hNVl,PSEQvF2=	MVLEUXNQ	MmWzTWM2OD1yLki1NkDPxE1?	NXS4WGFKOTl7OU[yO\|I>
M109	MkDjS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NES3NoF,PSEQvF2=	MUDEUXNQ	MkLCTWM2OD1zLkC1OUDPxE1?	NHexfFQyQTl7NkK3Ni=>
BT549	NGeyPGJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NH3GUWx,PSEQvF2=	M3XlSWROW09?	M3fybmlEPTB;MT62OFUh\|ryP	NGDVcHgyQTl7NkK3Ni=>
HCT116/VM46	NIfCWppIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVr+OUDPxE1?	M3;TUGROW09?	NV7rWoZMUUN3ME2xMlcxOiEQvF2=	NXvxUoxOOTl7OU[yO\|I>
H460	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M{jQXp42KM7:TR?=	Mln3SG1UVw>?	NULJR2RDUUN3ME2wMlc6PSEQvF2=	NXi3ZlJ7OTl7OU[yO\|I>
MCF-7	MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1nQO542KM7:TR?=	NFLyXXlFVVOR	NHTmfWlKSzVyPUCuNFE3KM7:TR?=	M3nSelE6QTl4Mkey
GEO	MorJS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHTV[2d,PSEQvF2=	NV\iNVdlTE2VTx?=	NIXK[YtKSzVyPUCuN\|U3KM7:TR?=	MoT5NVk6QTZ{N{K=
H441 0.646	M4fQNmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NELBU41,PSEQvF2=	M2PQZmROW09?	NGDP[FdKSzVyPUCuOlQ3KM7:TR?=	NWq1N25kOTl7OU[yO\|I>
MCF-7-807R	NImwTWxIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NIfUdY9,PSEQvF2=	M2riO2ROW09?	NVewS2VVUUN3ME2wMlQ6KM7:TR?=	M2fvWFE6QTl4Mkey
Colo205	M1Wy[Gdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MXn+OUDPxE1?	NULGNZpmTE2VTx?=	NWPtSppEUUN3ME2wMlExPCEQvF2=	NUn1blQ{OTl7OU[yO\|I>
H292	NGKySmRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWD+OUDPxE1?	NELh[I1FVVOR	M3rxXGlEPTB;MD63PFgh\|ryP	MoK1NVk6QTZ{N{K=
BT474 (S)	M4LCXmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NYG5e\|JEhjVizszN	MlHUSG1UVw>?	Ml7uTWM2OD1{LkSwN{DPxE1?	NG\Z[20yQTl7NkK3Ni=>
HT-29	NIPnVlZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NX7wXHFVhjVizszN	MmntSG1UVw>?	MXPJR\|UxRTJwMUCzJO69VQ>?	M1HGd\|E6QTl4Mkey
A549	MnT3S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVK1VGtmhjVizszN	M4DQXWROW09?	MoDiTWM2OD1yLk[3OUDPxE1?	NVr0d5Z{OTl7OU[yO\|I>
BT474-M1	MonWS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MofZglUh\|ryP	NGjvN2dFVVOR	MlrWTWM2OD1{LkO2OUDPxE1?	NIHZXWYyQTl7NkK3Ni=>
SW480	MoGyS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M2LMOp42KM7:TR?=	M{fGdWROW09?	MUfJR\|UxRjVwMECg{txO	NIDlW3MyQTl7NkK3Ni=>
L2987	M2\IU2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M136WZ42KM7:TR?=	NVfIdFVvTE2VTx?=	M33BcGlEPTB;MD60OFIh\|ryP	NGXCeIcyQTl7NkK3Ni=>
AU565	NF3Lb2JIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGXrZ45,PSEQvF2=	M{jmfmROW09?	MY\JR\|UxRTRwOUeg{txO	MYGxPVk6PjJ5Mh?=
SW403	NVfH[4FST3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M{DlUp42KM7:TR?=	NFvDRZFFVVOR	MoLTTWM2OD1yLkKyJO69VQ>?	MXuxPVk6PjJ5Mh?=
H1437	MWTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWG4eJVHhjVizszN	NUDkeI9PTE2VTx?=	MoHITWM2OD1yLkWyN{DPxE1?	M3e1c\|E6QTl4Mkey
BT-20	MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXXodI81hjVizszN	NXTSUJNkTE2VTx?=	NUTleWVkUUN3ME2zMlU3OiEQvF2=	NU\td2xvOTl7OU[yO\|I>
Colo320HSR	M4HNfmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MUT+OUDPxE1?	NUDFeXV1TE2VTx?=	MXzJR\|UxRTBwMEGxJO69VQ>?	MXSxPVk6PjJ5Mh?=
H2087	M4\MTWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mlj5glUh\|ryP	NI[1TYtFVVOR	NYHHPZA{UUN3ME6xMlAxKM7:TR?=	NHnOZWwyQTl7NkK3Ni=>
HCC1419	MVXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYP+OUDPxE1?	NXj6SFY{TE2VTx?=	NUHCe2JlUUN3ME2yMlUyPyEQvF2=	NF3zdIsyQTl7NkK3Ni=>
WiDr	MV3Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NUnHVno4hjVizszN	M1PNSWROW09?	MX7JR\|UxRTBwMEe2JO69VQ>?	M{fOW\|E6QTl4Mkey
H661 0.573	MXvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NXjNNo1[hjVizszN	NGq1b25FVVOR	MnL5TWM2OD1yLkW3N{DPxE1?	NW\Y[\|hROTl7OU[yO\|I>
HCC-38	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MkPjglUh\|ryP	MXzEUXNQ	MUXJR\|UxRjVwMECg{txO	M4\ZdlE6QTl4Mkey
LS174T	MVvHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MXj+OUDPxE1?	M1vlZmROW09?	NXfsNo1IUUN3ME2wMlU{PSEQvF2=	M1zLblE6QTl4Mkey
H211	M{[yVGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MX7+OUDPxE1?	MWLEUXNQ	NFGwRmxKSzVyPUCuO\|M{KM7:TR?=	NVzvVIlFOTl7OU[yO\|I>
HCC70	NXXqbVJ7T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NIfpXW9,PSEQvF2=	MXXEUXNQ	M3Pl[2lEPTB;MT61OUDPxE1?	NYr5bIZzOTl7OU[yO\|I>
SW116	MnfES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NVrY[GhChjVizszN	MmrHSG1UVw>?	MkfVTWM2OD1yLkC2O{DPxE1?	M4jQelE6QTl4Mkey
H513	NILaWoZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NUXIRpR7hjVizszN	NH;N[ItFVVOR	NV;xWJdmUUN3ME20MlQ1QCEQvF2=	MkHvNVk6QTZ{N{K=
MDA-MB-157	M4jtWmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NEHrdZN,PSEQvF2=	NXvGU4lKTE2VTx?=	MWLJR\|UxRTBwMEO2JO69VQ>?	M2jtSlE6QTl4Mkey
H2052	NEPzeHRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MmfzglUh\|ryP	M3L4b2ROW09?	M1XnO2lEPTB;MT6wOUDPxE1?	MVyxPVk6PjJ5Mh?=
MDA-MB-415	MUnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWj4ZWdPhjVizszN	M33VUGROW09?	MYLJR\|UxRjVwMECg{txO	NWT3NpFROTl7OU[yO\|I>
DLD-1	NFHX[pJIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NXvydlI3hjVizszN	NWjlNYE2TE2VTx?=	MkXXTWM2OD1yLkmwPUDPxE1?	MX[xPVk6PjJ5Mh?=
H2595	NVTC[WxUT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnjjglUh\|ryP	NYm1Wmp4TE2VTx?=	NXfmVYMxUUN3ME20MlQ4PSEQvF2=	MonMNVk6QTZ{N{K=
MDA-MB-435S	NWTmTZhGT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NWfmbWlDhjVizszN	MorESG1UVw>?	M12zNGlEPTB;MT64Olkh\|ryP	NWL5[WszOTl7OU[yO\|I>
HCT15	MmjES5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MoX1glUh\|ryP	MYrEUXNQ	MkLXTWM2OD5zLkCwJO69VQ>?	NIDlU4cyQTl7NkK3Ni=>
SK-Hep1	M3ntdmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NG\iS4N,PSEQvF2=	MXzEUXNQ	MnmyTWM2OD1yLkG0OkDPxE1?	MYOxPVk6PjJ5Mh?=
MDA-MB-436	NYThPW85T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NGXtemJ,PSEQvF2=	MXfEUXNQ	MY\JR\|UxRTVwNUCyJO69VQ>?	NGDHO\|cyQTl7NkK3Ni=>
KM12C	MV7Hdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NFq5blJ,PSEQvF2=	NYPmTo1qTE2VTx?=	MlK3TWM2OD1yLkC1OEDPxE1?	NELJOHQyQTl7NkK3Ni=>
HEPG2	MUjHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M3e2Vp42KM7:TR?=	MWHEUXNQ	MVXJR\|UxRTBwMEK1JO69VQ>?	M4rQWlE6QTl4Mkey
MDA-MB-453	MWrHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4\PUJ42KM7:TR?=	MlzsSG1UVw>?	NX3lWIdiUUN3ME2xMlg3QSEQvF2=	NYHJdZI6OTl7OU[yO\|I>
KM12SM	MYHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MYf+OUDPxE1?	NXXyRY9RTE2VTx?=	MVXJR\|UxRTBwMEW5JO69VQ>?	MVWxPVk6PjJ5Mh?=
1483	M4LzNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mm[2glUh\|ryP	MlOySG1UVw>?	Mny5TWM2OD1{LkG5JO69VQ>?	NVPWTpBPOTl7OU[yO\|I>
Hs578t	MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MUf+OUDPxE1?	M2q2PWROW09?	NFvmXWdKSzVyPUGuNlg4KM7:TR?=	MoTYNVk6QTZ{N{K=
LS180	M{Lp[mdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NF;FNlF,PSEQvF2=	NHzwepNFVVOR	MmT6TWM2OD1yLk[5OkDPxE1?	NFvNWWgyQTl7NkK3Ni=>
FaDu	MmT2S5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NHfaNI5,PSEQvF2=	MUPEUXNQ	NHrBe3FKSzVyPUGuNlch\|ryP	M33MfFE6QTl4Mkey
ZR-75-1	NWfvN2QyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NXW0NIRjhjVizszN	MVLEUXNQ	M3f1VWlEPTB;Mj6wPFQh\|ryP	NWDQbIdzOTl7OU[yO\|I>
LS513	M2rPNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M2DZTZ42KM7:TR?=	MnvMSG1UVw>?	NIrU[mJKSzVyPUCuNVM2KM7:TR?=	M33kS\|E6QTl4Mkey
Detroit.562	NXfPWnczT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHHDZ2d,PSEQvF2=	MVLEUXNQ	NF;1cGhKSzVyPUGuNVQh\|ryP	M4\LUVE6QTl4Mkey
ZR-75-30	NV3hUVFyT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NVXHNGZXhjVizszN	NWPkfYhDTE2VTx?=	MoKwTWM2OD53LkCwJO69VQ>?	MWGxPVk6PjJ5Mh?=
RKO-PM	M2f4bGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	Mor3glUh\|ryP	M173RmROW09?	M4HEdGlEPTB;MD6yN\|Ih\|ryP	M17PWVE6QTl4Mkey
Cal.27	NFXkPJlIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NHzjdFJ,PSEQvF2=	MnnRSG1UVw>?	M1\hbWlEPTB;MjFOwG0>	NWPlfG54OTl7OU[yO\|I>
KPL4	NYrzcFhkT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHXzUWV,PSEQvF2=	MYHEUXNQ	M{j5bWlEPTB;MT6yOVIh\|ryP	MojZNVk6QTZ{N{K=
PKO-RM13	NUTW[HFjT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MnzSglUh\|ryP	Ml3tSG1UVw>?	NEfYS2hKSzVyPUCuOFI2KM7:TR?=	NUPVPHBTOTl7OU[yO\|I>
HS.53.T	MYXHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MWT+OUDPxE1?	NHHk[2pFVVOR	NIjxU3pKSzVyPUCuO\|kh\|ryP	M1fpeVE6QTl4Mkey
EMT6	MkDaS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NH\1eWJ,PSEQvF2=	NGOwZnJFVVOR	NV;NSHI{UUN3ME2wMlgxPiEQvF2=	NFHnVIMyQTl7NkK3Ni=>
SNU-C1	M2DLZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MmCzglUh\|ryP	MV\EUXNQ	MY\JR\|UxRTBwMEC3JO69VQ>?	NUiwS4N[OTl7OU[yO\|I>
SQCCY1	NWHhZphbT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	MXX+OUDPxE1?	NYnPS4ZpTE2VTx?=	M2W0SWlEPTB;MD63PUDPxE1?	M2LlN\|E6QTl4Mkey
SW480	NFXkSoRIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MVH+OUDPxE1?	MYTEUXNQ	NGjEfW9KSzVyPUCuNFM4KM7:TR?=	NVnweW9WOTl7OU[yO\|I>
SCC9	M{O2eGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	M1zHUJ42KM7:TR?=	NIXQSIhFVVOR	NYPx[5YyUUN3ME2wMlc2KM7:TR?=	MlHQNVk6QTZ{N{K=
SK-LMS-1	Mn\KS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MnPHglUh\|ryP	NHzJRlZFVVOR	MV\JR\|UxRTBwNki3JO69VQ>?	MoDsNVk6QTZ{N{K=
SCC25	M2nqd2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnK0glUh\|ryP	M4LJXGROW09?	Ml;YTWM2OD1yLk[4JO69VQ>?	Mn3BNVk6QTZ{N{K=
U87	NUD0NZVLT3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	NHPjWYJ,PSEQvF2=	MlHpSG1UVw>?	NInGfphKSzVyPUCuPVUh\|ryP	MWexPVk6PjJ5Mh?=
SCC15	NGToSGpIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M3GyTJ42KM7:TR?=	Ml75SG1UVw>?	M32z[2lEPTB;MD62O{DPxE1?	NFzHZ24yQTl7NkK3Ni=>
T98G	NEfMWI5Iem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MoizglUh\|ryP	M2nIRmROW09?	M{jOdWlEPTB;MT6yNVgh\|ryP	NYnQXHBjOTl7OU[yO\|I>
SCC4	MkfxS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MUX+OUDPxE1?	MnfYSG1UVw>?	NED5eoZKSzVyPUCuOlMh\|ryP	MkDkNVk6QTZ{N{K=
U118	Mn3lS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NV7vW\|l2hjVizszN	M3m1ZmROW09?	MYHJR\|UxRTFwNkG4JO69VQ>?	MWCxPVk6PjJ5Mh?=
TU167	MXPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M4X4bJ42KM7:TR?=	NX3yVpF4TE2VTx?=	MXzJR\|UxRTRwNUKg{txO	MmPBNVk6QTZ{N{K=
NCI-H727	MXHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NX7sNItlhjFy4pEK{txO	NFizSVZFVVOR	MXjJR\|UxRTR{ODDuUS=>	NWDiTmREOjB\|OEW3OFc>
NCI-H720	M1H0Smdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NF3ZcZd,OTEkgJtOwG0>	NFLENHZFVVOR	M3HLZWlEPTB;Mj64JO69VQ>?	NXPYS3psOjB\|OEW3OFc>
NCI-H835	Ml3kS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYD+NVDjiIsQvF2=	M13qNWROW09?	MoHETWM2OD1zIN88US=>	MmmzNlA{QDV5NEe=
NCI-H727	NHvXO\|RMcW6jc3WgZZN{[Xl?	NWDnOnZDhjFy4pEK{txO	NHz2fotFVVOR	NXzLVmFKcW6qaXLpeJMh[2:wc4TpeJV1cX[nIFnHSlFTKGG3dH;wbI9{eGixconsZZRqd25?	M2Dl[VIxOzh3N{S3
RD	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NE\UbY5,OTEkgJtOwG0>		MX7JR\|UxRTFwMUKgxtVO	MVyyNVI6QDd2NR?=
Rh41	MUTHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M2rPWJ4yOOLCit88US=>		M4Hae2lEPTB;MD6wO{DDvU1?	NHKw[XQzOTJ7OEe0OS=>
Rh18	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M365[p4yOOLCit88US=>		NHPpNJpKSzVyPUSuPVYhyrWP	Mn7XNlEzQTh5NEW=
Rh30	MYnHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MW\+NVDjiIsQvF2=		NYHadYlzUUN3ME2wMlE6KML3TR?=	MknyNlEzQTh5NEW=
BT-12	NEDZe3pIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWX+NVDjiIsQvF2=		NEHKNWNKSzVyPUCuO\|ghyrWP	M{jobVIyOjl6N{S1
CHLA-266	Ml7MS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MmHKglEx6oDMzszN		M4jxR2lEPTB;MD64PUDDvU1?	MmW0NlEzQTh5NEW=
TC-71	M3LyT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MnPuglEx6oDMzszN		M4T5eWlEPTB;MD6xNUDDvU1?	MWWyNVI6QDd2NR?=
CHLA-9	M4LOcWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MX7+NVDjiIsQvF2=		Mnm4TWM2OD1yLkGyJOK2VQ>?	Mn;ZNlEzQTh5NEW=
CHLA-10	MXLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVj+NVDjiIsQvF2=		NGK4UFBKSzVyPUCuOlIhyrWP	NFW2[4ozOTJ7OEe0OS=>
CHLA-258	NIS3UpBIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	NGPndZV,OTEkgJtOwG0>		NWf1UWVIUUN3ME2wMlI4KML3TR?=	M{W4RVIyOjl6N{S1
GBM2	NYnad\|Y5T3Kxd4ToJIlvcGmkaYTvdpkh[XO\|YYm=	M1yzOp4yOOLCit88US=>		NGSwW2tKSzVyPUGuOFchyrWP	M2DMelIyOjl6N{S1
NB-1643	NEfFSFZIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	M2q4U54yOOLCit88US=>		MWLJR\|UxRTBwMUKgxtVO	NGXzOJEzOTJ7OEe0OS=>
NB-EBc1	MmjSS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	MYX+NVDjiIsQvF2=		Mke2TWM2OD1yLkO1JOK2VQ>?	Moj4NlEzQTh5NEW=
CHLA-90	MYDHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MojWglEx6oDMzszN		MYDJR\|UxRTBwN{egxtVO	M3\wR\|IyOjl6N{S1
CHLA-136	MWfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1PPOp4yOOLCit88US=>		NHTCPGZKSzVyPUCuOVIhyrWP	MYeyNVI6QDd2NR?=
NALM-6	MYfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	M1rvT54yOOLCit88US=>		NVrwNG5EUUN3ME2wMlQ6KML3TR?=	MYGyNVI6QDd2NR?=
COG-LL-317	M4jKOGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NEXFbJV,OTEkgJtOwG0>		MkD2TWM2OD1zLkO4JOK2VQ>?	Mk\hNlEzQTh5NEW=
RS4;11	NH7SNpNIem:5dHigbY5pcWKrdH;yfUBie3OjeR?=	MWf+NVDjiIsQvF2=		MoG1TWM2OD1yLkO4JOK2VQ>?	M2TYXFIyOjl6N{S1
MOLT-4	MVfHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	MVT+NVDjiIsQvF2=		M{TGR2lEPTB;MD61N{DDvU1?	Mof3NlEzQTh5NEW=
CCRF-CEM	MWPHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>?	NWC1fVVHhjFy4pEK{txO		NV7X[mJqUUN3ME2xMlE{KML3TR?=	M2HJUVIyOjl6N{S1
Kasumi-1	MojOS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NFfVfWJ,OTEkgJtOwG0>		NH3FUnRKSzVyPUGuNkDDvU1?	M37QTFIyOjl6N{S1
Karpas-299	MmjkS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	NF7qbVV,OTEkgJtOwG0>		M4fMOWlEPTB;MT62OEDDvU1?	NELETo4zOTJ7OEe0OS=>
Ramos-RA1	M1TITWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	MonrglEx6oDMzszN		Mkm1TWM2OD1zLkOxJOK2VQ>?	NUnsSXBWOjF{OUi3OFU>
Rh30	MlXSSpVv[3Srb36gZZN{[Xl?			Mn\UbY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w	NUn3SoU{OjV7MkWzO\|g>
Rh41	MUjGeY5kfGmxbjDhd5NigQ>?			MkG3bY5lfWOnczDhckBqdmO{ZXHz[UBw\iCVRlugdIhwe3Cqb4L5cIF1cW:w	NGDKT4QzPTl{NUO3PC=>
RD	MmHYSpVv[3Srb36gZZN{[Xl?			MVjpcoR2[2W\|IHHuJIlv[3KnYYPlJI9nKFOISzDwbI9{eGixconsZZRqd25?	MmP3NlU6OjV\|N{i=
A549	NV3SWGxjU2mwYYPlJIF{e2G7	MWSwMlXjiIsQvF2=	M2\ZZ2ROW09?	NF76fJRqdmirYnn0d{BKT0ZvSWKvTXIh[WO2aY\heIlwdg>?	Mkn2NlY6Ojh3N{i=
NCI-H358	NWnYVGdDU2mwYYPlJIF{e2G7	NFH0b\|AxNjYkgJtOwG0>	M{TVfmROW09?	MXjpcohq[mm2czDJS2YuUVJxSWKgZYN1cX[jdHnvci=>	NUPYSmwxOjZ7Mki1O\|g>
A549	M1:1VGZ2dmO2aX;uJIF{e2G7	MlzyNE426oDMzszN	M4\SNGROW09?	NWHEcpg6[2G3c3XzJIEh[2:wY4XydoVvfCCmZXPy[YF{\SCrbjDwbI9{eGixconsZZRm\CCDS2SgZY5lKEWUSx?=	NYDLVGQ5OjZ7Mki1O\|g>
NCI-H358	NYTVTW8{TnWwY4Tpc44h[XO\|YYm=	NFy0RlMxNjYkgJtOwG0>	MUnEUXNQ	MX;jZZV{\XNiYTDjc45kfXK{ZX70JIRm[3KnYYPlJIlvKHCqb4PwbI9zgWyjdHXkJGFMXCCjbnSgSXJM	NHLURVUzPjl{OEW3PC=>
A549	M3nEdWdzd3e2aDDpcohq[mm2b4L5JIF{e2G7	NVi2VlZ2hjFy4pEK{txO	NUW3WG5DTE2VTx?=	MV\JR\|UxRTBwN{[g{txO	NH70UoUzPjl{OEW3PC=>
NCI-H358	MmXaS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl?	M3nHT54yOOLCit88US=>	Ml:3SG1UVw>?	MULJR\|UxRTFwMEmg{txO	NHHmW2IzPjl{OEW3PC=>
A549	MYTBdI9xfG:\|aYOgZZN{[Xl?	MnfrNE426oDMzszN	NGDXUZlFVVOR	MUjpcoR2[2W\|IFHwc5B1d3Orcx?=	NHn0SIQzPjl{OEW3PC=>
NCI-H358	M{n3[2Fxd3C2b4Ppd{Bie3OjeR?=	MnXNNE426oDMzszN	M4\zfGROW09?	MoXibY5lfWOnczDBdI9xfG:\|aYO=	NVXwN3lxOjZ7Mki1O\|g>
A549	NGHJUHZHfW6ldHnvckBie3OjeR?=	NEPaTFAxNjYkgJtOwG0>	Mn;FSG1UVw>?	MnHndoVlfWOnczD3c5Vv\CClbH;zeZJm	MYKyOlkzQDV5OB?=
NCI-H358	NWnIU4FXTnWwY4Tpc44h[XO\|YYm=	MmLmNE426oDMzszN	M3XvVGROW09?	NWWzVFl2emWmdXPld{B4d3WwZDDjcI9{fXKn	Mki2NlY6Ojh3N{i=

... Click to View More Cell Line Experimental Data

In vivo

BMS-754807 (12.5mg/kg, orally) inhibits IGF-1R phosphorylation in tumor and serum in IGF-1R-Sal tumor–bearing nude mice. BMS-754807 inhibits tumor growth in a selected group of epithelial (IGF-1R-Sal, GEO, and Colo205), hematopoietic (JJN3), and mesenchymal (RD1 and Rh41) xenograft tumor models with TGI ranging from 53% to 115%. ^[1] BMS-754807 (6.25 mg/kg) achieves complete tumor growth inhibition in the transgenic-derived IGF-Sal tumor mouse model with correlated inhibition of pIGF-1R and pAKT. The protein binding for BMS-754807 ranges from of 98.5% in mouse plasma to 95.9% in human plasma. BMS-754807 results in clearance of 113 (mL/min)/kg, 20 (mL/min)/kg, 3.5 (mL/min)/kg and 41 (mL/min)/kg. ^[2] BMS-754807 (25 mg/kg) significantly inhibits tumor in KT-5 (Wilms), KT-14 (rhabdoid), Rh28 (rhabdomyosarcoma), and OS-1 xenografts mice model. ^[3]

Protocol

Kinase Assay:^[1]	+ Expand Kinase inhibition assays: The primary screen for BMS-754807 is an in vitro kinase assay using recombinant human IGF-1 receptor enzyme in biochemical assays using synthetic peptide KKSRGDYMTMQIG as a phosphoacceptor substrate. The selectivity profile is evaluated against multiple recombinant enzymes that are generated at BMS or purchased externally. The enzymatic assays are performed in Ubottom 384-well plates using a 30 μL reaction volume in assay buffer (100 mM Hepes pH 7.4, 10 mM MgCl₂, 0.015% Brij35 and 4 mM DTT). The 60 minute reactions are initiated by combining ATP (concentration equivalent to K_m ATP), 1.5 μM fluoresceinlabeled peptide substrate, enzyme and BMS-754807. The reactions are terminated with EDTA. The reaction mixtures are analyzed on the Caliper LabChip 3000 by electrophoretic separation of the fluorescent substrate and phosphorylated product. Inhibition data are calculated by comparison to enzyme-free control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. Compounds are dissolved in dimethylsulfoxide (DMSO, 10mM stock) and evaluated at eleven concentrations. IC50 values are derived by non-linear regression analysis of the dose response curves.
Cell Research:^[1]	+ Expand Cell lines: IGF-1R-Sal, RH41 and Geo cell lines Concentrations: 365 nM Incubation Time: 72 hours Method: Cells are grown at their optimal density in RPMI +GlutaMax supplemented with 10% heat-inactivated fetal bovine serum (FBS), 10 mM Hepes, penicillin, and streptomycin. Cell proliferation is evaluated by incorporation of ³H-thymidine into DNA after exposure of cells to BMS-754807 for 72 hours. Results are expressed as an IC50, which is the drug concentration required to inhibit cell proliferation by 50% compared with untreated control cells. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: IGF-1R-Sal, GEO, Colo205, JJN3, RD1 or Rh41 tumor–bearing nude mice Formulation: Mixture of polyethylene glycol 400 (PEG400/water (4:1; vol/vol) Dosages: 150 mg/kg Administration: Orally (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	92 mg/mL (199.35 mM)
	Ethanol	92 mg/mL (199.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BMS-754807 SDF

Molecular Weight	461.49
Formula	C₂₃H₂₄FN₉O
CAS No.	1001350-96-4
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	February 2012	Phase 1
NCT01525823	Completed	Healthy Volunteers	Bristol-Myers Squibb	February 2012	Phase 1
NCT01225172	Completed	Breast Cancer	Bristol-Myers Squibb\|Mayo Clinic	December 2010	Phase 2
NCT01225172	Completed	Breast Cancer	Bristol-Myers Squibb\|Mayo Clinic	December 2010	Phase 2
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	October 2009	Phase 1\|Phase 2
NCT00908024	Terminated	Colorectal Cancer\|Head and Neck Cancer\|Neoplasm Metastasis	Bristol-Myers Squibb	October 2009	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Selective IGF-1R Inhibitor

NVP-AEW541 : IGF-1R-selective, IC50=86 nM.
IGF-1R Inhibitor in Clinical Trial

OSI-906 (Linsitinib) : Phase II for Advanced Solid Tumors.
Newest IGF-1R Inhibitor

PQ 401 : Inhibitor of autophosphorylation of IGF-1R domain with IC50 of <1 μM.
Classic IGF-1R Inhibitor

BMS-536924 : ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.

Related IGF-1R Products4

Picropodophyllin (PPP) ^New

Picropodophyllin (PPP) is a IGF-1R inhibitor with IC50 of 1 nM. It displays selectivity for IGF-1R and does not coinhibit tyrosine phosphorylation the IR, or of a selected panel of receptors less related to IGF-IR(FGF-R, PDGF-R, OR EGF-R).
Erlotinib ^New

Erlotinib is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
R428 (BGB324) ^New

R428 (BGB324) is an inhibitor of Axl with IC50 of 14 nM, >100-fold selective for Axl versus Abl. Selectivty for Axl is also greater than Mer and Tyro3 (50-to-100- fold more selective) and InsR, EGFR, HER2, and PDGFRβ (100- fold more selective).
BMS-536924

BMS-536924 is an ATP-competitive IGF-1R/IR inhibitor with IC50 of 100 nM/73 nM, modest activity for Mek, Fak, and Lck with very little activity for Akt1, MAPK1/2.
NVP-AEW541

NVP-AEW541 is a potent inhibitor of IGF-1R/InsR with IC50 of 150 nM/140 nM in cell-free assays, greater potency and selectivity for IGF-1R in a cell-based assay.
NVP-ADW742

NVP-ADW742 is an IGF-1R inhibitor with IC50 of 0.17 μM, >16-fold more potent against IGF-1R than InsR; little activity to HER2, PDGFR, VEGFR-2, Bcr-Abl and c-Kit.
Linsitinib (OSI-906)

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
GSK1904529A

GSK1904529A is a selective inhibitor of IGF-1R and IR with IC50 of 27 nM and 25 nM in cell-free assays, >100-fold more selective for IGF-1R/InsR than Akt1/2, Aurora A/B,B-Raf, CDK2, EGFR etc.
AG-1024

AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins).
PQ 401

PQ401 inhibits autophosphorylation of IGF-1R domain with IC50 of <1 μM.

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 6 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Choose Your Country or Region

By Signaling Pathways

By product type

BMS-754807

Cited by 6 Publications

1 Customer Review

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BMS-754807 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)